International Journal of Clinical Research

Objective: To explore the clinical application in the treatment of hand, foot and mouth disease α Value of 2B (recombinant interferon). Methods: a total of 60 subjects were selected from the Department of nosocomial infection from February 2021 to March 2022. All subjects were randomly divided into study group and control group, with an average of 30 people in each group. Different treatment methods were used in the group to compare the final therapeutic effect and the change of patient pain index. Results: in the study group, the total effective rate was significantly higher (P; Before treatment, there was little difference in the degree of oral pain between groups; After treatment, the pain scores of the two groups decreased, but the scores of the study group were significantly lower. The study data excluded the pre-treatment and 1 day after treatment, and the other values were compared (P < 0.05).；After treatment, the symptoms of both children with HFMD improved. In the study group, symptoms with high fever, herpes and rash subsided faster and the total hospitalization was shorter, P <0.05.Conclusion: for HFMD α The clinical efficacy of 2B (recombinant interferon) is significant, and the pain index of children gradually decreases after treatment, which is suitable for active promotion.

Recombinant Interferon; α 2B; Hand foot Mouth Disease; Therapeutic Value